In participants with acute schizophrenia, TAAR1 agonists showed little difference compared to placebo in improving overall symptoms measured by PANSS total over a treatment of 4–6 weeks (number of studies N=4, number of participants n=1291, SMD=0.15, 95%CI: -0.05 to 0.34) (Figure 2A). The gene discussed is TAAR1; the disease is schizophrenia.